Dry eye is a common clinical condition diagnosed by cumulative evidence of symptoms and signs.Many new treatments in dry eye are either expensive,invasive,have potential for side effects,or are not easily accessible.I...Dry eye is a common clinical condition diagnosed by cumulative evidence of symptoms and signs.Many new treatments in dry eye are either expensive,invasive,have potential for side effects,or are not easily accessible.In severe dry eye,the ideal modality of treatment to begin with is often not clear as specific molecular disturbances are not evident from just examination of clinical manifestations.Assessing the effects of ongoing treatment is not straight forward since there is lack of agreement between clinical signs and symptoms.There is a need to have more objective methods of selecting treatment for dry eye and monitoring the effect of treatment.Recently,there are many new technologies applied to the discovery of tear biomarkers,for e.g.,mass spectrometry based proteomics techniques and multiplex assays such as the bead-based sandwich indirect immunofluorescent assays.Tear proteins assays have even been made available as point-of-care devices.This review focuses on the evidence for the involvements of tear proteins in dry eye,possible changes in tear concentrations with therapy and the strength of evidence regarding dry eye pathology.Much remains to be done in terms of developing office-based assays and ascertaining their reliability,but current evidence suggests that tear proteins have a role in the clinical practice of dry eye.展开更多
基金National Medical Research Council grants,NMRC/CSA/045/2012.
文摘Dry eye is a common clinical condition diagnosed by cumulative evidence of symptoms and signs.Many new treatments in dry eye are either expensive,invasive,have potential for side effects,or are not easily accessible.In severe dry eye,the ideal modality of treatment to begin with is often not clear as specific molecular disturbances are not evident from just examination of clinical manifestations.Assessing the effects of ongoing treatment is not straight forward since there is lack of agreement between clinical signs and symptoms.There is a need to have more objective methods of selecting treatment for dry eye and monitoring the effect of treatment.Recently,there are many new technologies applied to the discovery of tear biomarkers,for e.g.,mass spectrometry based proteomics techniques and multiplex assays such as the bead-based sandwich indirect immunofluorescent assays.Tear proteins assays have even been made available as point-of-care devices.This review focuses on the evidence for the involvements of tear proteins in dry eye,possible changes in tear concentrations with therapy and the strength of evidence regarding dry eye pathology.Much remains to be done in terms of developing office-based assays and ascertaining their reliability,but current evidence suggests that tear proteins have a role in the clinical practice of dry eye.
